A randomized, double-blind, placebo controlled, section III medical demo evaluated the efficacy and basic safety profile of adalimumab being a monotherapy in patients with RA who had failed to reply to csDMARDs [191]. The results confirmed each statistically sizeable improvement while in the illness action and a great protection profile. https://www.directivepublications.org/journal-of-arthritis-and-rheumatology/